You are viewing the site in preview mode
Skip to main content
| Characteristics | PBB |
|---|
| Gender, M(F) | 33 (19) |
| Age |
| <1y | 15 (28.8%) |
| 1-3y | 16 (30.8%) |
| 3-6y | 15 (28.8%) |
| 6-14y | 6 (11.5%) |
| Course |
| >4 week | 19 (36.5%) |
| 4-12 week | 14 (26.9%) |
| >12 week | 19 (36.5%) |
| Symptoms |
| Wet cough | 52 (100%) |
| Purulent sputum | 13 (25%) |
| Cough both day and night | 22 (42.3%) |
| Wheezing | 15 (28.8%) |
| Fever | 11 (21.2%) |
| Nasal symptoms | 19 (36.5%) |
| Physical examination |
| Lung moist rales | 30 (57.7%) |
| Lung wheezing rales | 3 (5.8%) |
| Microbiological findings | 13 (25%) |
| Positive bacterial cultures of Sputum | 11 (21.2%) |
| Spn | 8 (15.4%) |
| Sa | 2 (3.8%) |
| Pae | 1 (1.9%) |
| Positive bacterial cultures of BALF | 2 (3.8%) |
| Spn | 1 (1.9%) |
| Sa | 1 (1.9%) |
| Comorbidities |
| Rhinitis | 7 (13.5%) |
| Sinusitis | 5 (9.6%) |
| Laryngomalacia | 3 (5.8%) |
| Airway stenosis | 1 (1.9%) |
| Treatment |
| Antibiotic |
| Amo | 6 (11.5%) |
| Cep (oral) | 15 (28.8%) |
| Cep (intravenous) | 26 (50%) |
| Azi | 5 (9.6%) |
| Duration | 3d-2w |
| Effects |
| Remission | 20 (38.5%) |
| Improve | 24 (46.2%) |
| No improvement | 8 (15.3%) |
| Complication | 0 |
- Values are expressed as n (%). M: male; F: female. Spn: Streptococcus pneumonia; Sa: Staphylococcus aureus; Pae: Pseudomonas aeruginosa. Amo:Amoxicillin-clavulanate; Cep: cephalosporin antibiotics; Azi: Azithromycin.
